Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204775 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
A Phase 3 study of Type 2 Diabetes, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
- 16
- Study locations
NCT01204775: Completed Phase 3 study of Type 2 Diabetes, sponsored by AstraZeneca.
NCT01204775 is a Phase 3 study of Type 2 Diabetes that has completed, run by AstraZeneca. The registered enrollment target is 26 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 16 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01204775, a Phase 3 study of Type 2 Diabetes, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability, of Saxagliptin in pediatric patients with type 2 diabetes.
Conditions Studied
Interventions
- DRUG Saxagliptin
- DRUG Metformin IR
- DRUG Placebo (Saxagliptin)
- DRUG Placebo (Metformin)
- DRUG Metformin (Active Rescue)
Study Locations (16)
Other
- Research Site - Moscow
- Research Site - Novosibirsk
- Research Site - Saint Petersburg
- Research Site - Cape Town
- Research Site - Pretoria
- Research Site - Taichung
- Research Site - Taipei
Florida
- Research Site - Hollywood
- Research Site - Tallahassee
- Research Site - Tampa
California
- Research Site - Los Angeles
- Research Site - San Diego
Michigan
- Research Site - Dearborn
New York
- Research Site - Buffalo
Tennessee
- Research Site - Memphis
Virginia
- Research Site - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2011-06 |
| Est. Completion | 2016-04 |
| Phase | Phase 3 |
What the finished NCT01204775 record still lists
NCT01204775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 5 interventions - of which Saxagliptin is the first listed.
NCT01204775 lists 16 locations in 7 states (Other, Florida, California).
Frequently Asked Questions
What is clinical trial NCT01204775 about?
NCT01204775 is a clinical study titled "Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes". The purpose of this study is to evaluate the efficacy, safety, tolerability, of Saxagliptin in pediatric patients with type 2 diabetes.
What is the current status of trial NCT01204775?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2011-06. Estimated completion is 2016-04.
What conditions does trial NCT01204775 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT01204775?
The interventions under investigation include: Saxagliptin (DRUG), Metformin IR (DRUG), Placebo (Saxagliptin) (DRUG), Placebo (Metformin) (DRUG), Metformin (Active Rescue) (DRUG).
Who is sponsoring clinical trial NCT01204775?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01204775 being conducted?
This trial has 16 study locations across California, Florida, Michigan, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01204775's enrollment target sits among peer trials
26 273rd of 327 higher than 53 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia